Total Funding
73
95
Total FundingSeries C raised
Growth Score
-6 pts
Heat Score
30 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
716
Allotera Therapeutics is developing off-the-shelf cellular therapies targeting solid tumors and hematologic malignancies
- Ayman Kabakibi: Chief Operating Officer, Executive Vice President of Research & Development
John McKearn: CHIEF EXECUTIVE OFFICER AND PRESIDENTPast Role: Pharmacia, Scientist
About the Company
Allotera Therapeutics is off-the-shelf cellular therapies for cancer. Our NK cell therapy products originate from healthy donors and are further manipulated in order to enhance their function to eliminate cancer cells. Our NK cell and CAR-T immuno-oncology therapies address the needs of patients with solid tumors, acute myeloid leukemia (AML) and
T-cell malignancies.
